Última Hora: "Jerónimo diz que não "assina de cruz" o próximo Orçamento - Público.pt" Sat, 23 Jun 2018 09:39:14 GMT    "Jerónimo de Sousa: Críticas ao PCP por causa dos combustíveis são ?conversa fiada? - Observador" Fri, 22 Jun 2018 23:44:00 GMT    "Costa: Défice está ?em linha? com o previsto, mas não há ?folgas mágicas? - Observador" Fri, 22 Jun 2018 19:07:00 GMT   "" Sat, 23 Jun 2018 16:43:34 GMT    "A partir de 2.ª feira, pode levar o seu cão a tomar café. Mas lei não é clara... - TSF Online" Fri, 22 Jun 2018 17:30:43 GMT    "Trabalhadores da Groundforce pedem mais efetivos como medida de segurança face a agressões - Expresso" Fri, 22 Jun 2018 17:29:00 GMT    "As seis decisões do Eurogrupo que marcam o fim do resgate à Grécia - Jornal de Negócios - Portugal" Fri, 22 Jun 2018 16:23:16 GMT    "Opinião. Fernando Guedes. 'Sograpiness forever' - Dinheiro Vivo" Sat, 23 Jun 2018 11:13:28 GMT    ""Foi um grande erro destruir a rede de elétricos em Lisboa" - Diário de Notícias - Lisboa" Fri, 22 Jun 2018 23:27:00 GMT    "Triciclo, o veículo precursor do automóvel - Diário de Notícias - Lisboa" Sat, 23 Jun 2018 15:03:00 GMT      Para mais notícias, clique aqui.

Área de Acesso
       
       
Lembrar Sempre 
(Login BolsaPT & Canal Forex)

Sem variação
Sepracor Inc. - [Ticker: SEPR]Gráfico Sepracor Inc.  Notícias Sepracor Inc.  Download de Históricos Metastock Sepracor Inc. e Outros  Análise Técnica Sepracor Inc.  
Última Trade0,000Range 52 Semanas[0,000 - 0,000]
Hora da Última Trade - 00:00:00Price-Target 1 Ano0,000
VariaçãoN/A (N/A)Capitalização Bolsista0
Bid / AskN/AEPS0,00
Abertura0,000PER0,00%
Máximo0,000Pagamento Dividendo
Mínimo0,000Data Ex-Dividendo
Fecho Anterior0,000Yield
Volume0Volume Médio (3m)0
Nota: Os dados podem apresentar atraso de alguns minutos.
Ver cotações de outros activos

Intraday   5 dias   1 mes   3 meses   6 meses   1 ano   2 anos   5 anos   10 anos            Use este gráfico no seu website!
Gráfico de Sepracor Inc. -  [Ticker: SEPR]
Mudar para Gráfico de Análise Técnica Interactiva de Sepracor Inc.

Últimos 10 Tópicos no Fórum sobre Sepracor Inc.:
Não foram encontrados tópicos sobre Sepracor Inc. [SEPR], mas aconselha-se pesquisa no Fórum por tópicos relacionados com Sepracor Inc..

 Notícias sobre Sepracor Inc. [SEPR]:   (ordenadas por relevância)

Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer
GlobeNewswire (press release)
Mr. Hastings also previously served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc. During his tenure at ArQule, he played an important role in ArQule's transition into a drug discovery and development organization, and in two ...


Desloratadine Market Analysis 2018-2025: Top Vendors Like Pfizer, Teva, Mylan, Sepracor, Sandoz, Abbott, Takeda
Digital Journal
New York, NY -- (SBWIRE) -- 06/11/2018 -- The Study Paper on Top key vendors in Desloratadine Market includes are Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, ...


Sleep Disturbances in Elderly Patients: June 2018
Healio
Sponsorship Statement: This CME activity is jointly sponsored by AKH Inc., Advancing Knowledge in Healthcare and Psychiatric Annals. ... Faculty members report the following financial relationships: Andrew A. Nierenberg, MD, has disclosed the following ...


Obstructive Lung Disease Market to See a Glorifying Development By 2023: Foresees MRFR
Industry Today (press release)
... Pfizer Inc. (U.S), Mylan (U.S.), Aerovance Inc. (U.S.), Alkermes Inc. (U.S.), Almirall SA. (U.S.), Genentech Inc. (U.S.), Sepracor, Inc. (U.S.), Skyepharma plc (U.S.). Get 120 Pages Premium Copy @ https://www.marketresearchfuture.com/sample_request ...

e mais »

Global Desloratadine Market 2018 ? Pfizer, Teva, Wante Pharmaceutical, Novartis India Limited, Mylan, Sepracor ...
First News 24
?Global Desloratadine Market Size, Status and Forecast 2025 provides Market information about industry Top Key Players, Countries, Type and Application. This Desloratadine Industry report also states Company Profile, sales, Desloratadine Market revenue ...


Business Wire (press release)

Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
Business Wire (press release)
Prior to Auxilium, he was Vice President, General Counsel and Corporate Secretary of Enobia Pharma, Inc. Prior to that, Mr. Trachtenberg served as Vice President and Associate General Counsel of Sepracor Inc. (now known as Sunovion Pharmaceuticals ...

e mais »

Business Wire (press release)

BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, MD, as ...
Business Wire (press release)
Dr. Currie has over 25 years of drug development experience in both pharmaceutical and biotechnology companies, having held senior leadership roles at Dynavax Technologies Corp., Regeneron Pharmaceuticals, Sepracor Inc. and PDL Biopharma.

e mais »

Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer
Business Wire (press release)
Prior to joining Dyax, Todd was at Sunovion Pharmaceuticals, Inc. (previously Sepracor Inc., prior to its acquisition by Sumitomo Dainippon Pharma Co., Ltd), where he served in several roles of increasing responsibility including Vice President ...

e mais »

Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, MD to its Board of Directors
GlobeNewswire (press release)
In addition to his experience at Pfizer, Dr. Harrigan previously served as President & CEO of Karuna Pharmaceuticals, and in senior clinical leadership positions at Neurogen Corp. and Sepracor, Inc. Prior to entering the pharmaceutical industry in 1990 ...

e mais »

Business Wire (press release)

Entasis Therapeutics Appoints David C. Hastings to Board of Directors
Business Wire (press release)
BUSINESS WIRE)--Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of David C. Hastings to the company's Board of ...

e mais »

Business Wire (press release)

Rodin Therapeutics Expands Leadership Team, Adding Extensive Experience in Clinical and Business Development
Business Wire (press release)
She then joined Sunovion Pharmaceuticals, Inc. (formerly Sepracor), moving through positions of increasing responsibility into the role of vice president for corporate development and licensing. Sullivan played an instrumental role in the company's ...


Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors
Business Wire (press release)
From 2007-2010, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Sepracor Inc., where he was responsible for the company's legal and government affairs departments and Corporate Secretarial function until its ...

e mais »

The Boston Globe

Japanese executives ponder investing in Mass.
The Boston Globe
They visited a giant laboratory in Cambridge shared by emerging biotech companies and walked the life sciences mecca that is Kendall Square. They met with government officials who want to lure foreign companies to Massachusetts. They even saw the ...


GlobeNewswire (press release)

Spero Announces Appointment of David P. Southwell to its Board of Directors
GlobeNewswire (press release)
01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced ...

e mais »

Sunovion Pharmaceuticals Inc. Announces Company Name Change
Business Wire (press release)
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion), formerly Sepracor Inc. (Sepracor), announced today that it has formally changed its name. The change occurs on approximately the one year anniversary of the ...

e mais »
Para mais notícias sobre Sepracor Inc. clique aqui:
Notícias de Sepracor Inc.

Largura do Site:

 Imagem de Fundo:

Copyright@1998-2018 - BolsaPT.com, todos os direitos reservados.
Fórum de Bolsa Cotações de Bolsa Notícias de Bolsa Chat de Bolsa Disclaimer Recursos para Webmasters